Peter, I appreciate your reply. The company claims ISAtx247 is not only less toxic but 500% more potent. I have included a press release and a link to an analyst report that is very detailed.
"
ISATX247 TESTED ON ORGAN TRANSPLANT PATIENTS AS PHASE II TRIALS BEGIN
Edmonton, Alberta, August 2nd, 2001 - Isotechnika announced today that an Edmonton area person has become the first kidney transplant patient to be enrolled in Phase ll trials of the company’s novel immunosuppressive drug ISATX247. Within the next few months 120 patients at 13 transplant sites around North America including Stanford in the U.S., and four Canadian Universities including the University of Alberta, will be enrolled in the study. The trials will involve taking patients off of cyclosporine - the key anti-rejection drug - and putting them on ISATX247.
According to Isotechnika President and COO, Dr. Randall Yatscoff, patients involved in the trials received new kidneys at least six months ago. "We’ll be monitoring them closely during the three month trial period to ensure safety, however we expect the drug to improve the overall health of participants."
Isotechnika received approval from both the FDA and Health Canada to begin Phase II clinical trials on kidney transplant patients after completion of 22 separate studies. Because ISATX247 is a multi-platform drug and shows potential for treating a range of autoimmune diseases, Health Canada has also given the company the green light to begin similar testing of it on Psoriasis and Rheumatoid Arthritis Patients.
Research has shown that ISATX247 is up to 500% more potent than cyclosporine while demonstrating considerably less toxic side effects. Stanford University’s Director of Transplantation, Dr. Randall Morris sees great potential for ISATX247. He says: "The reduced toxicity and increased potency of ISATX247 suggests that the drug will have significant therapeutic advantages over currently used immunosuppressive medications".
Before the end of the year Isotechnika expects to be conducting tests on patients with Psoriasis and Rheumatoid Arthritis in addition to Kidney Transplants at more than 50 clinical centers and universities throughout North America.
Isotechnika CEO, Dr. Robert Foster says: "The approval of ISATX247 for trials in these three fields of medicine gives us confidence that we have a new drug that is very significant." Dr Foster adds: "The fact that we have a drug with so many possible uses should be reassuring to investors." The market for cyclosporine in transplantation therapy and as a treatment for autoimmune diseases is probably in excess of $2 billion (USD) per year.
About Isotechnika
Isotechnika is a life-sciences company headquartered in Edmonton, Alberta, Canada. The Company’s lead drug is ISATX247; a novel platform drug designed to prevent organ rejection following transplantation as well as the treatment of autoimmune diseases. Isotechnika also globally markets and distributes its internally developed breath-test diagnostic product line. One of these products, the Helikit, is regarded as the gold standard for the diagnosis of ulcers."
isotechnika.com
The link above is to Isa's home page. At the bottom right hand corner is an icon for "analyst report" The Pacific International Jan. 12 2001 is the best read. The Northern Securities is a more recent report and is also very detailed. |
